Loading
A phase 1/2 trial of atumelnant in pituitary tumours and pituitary carcinoma, run by Crinetics Pharmaceuticals Inc., active and no longer recruiting.
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome is a phase 1/2 interventional study registered as NCT05804669 by Crinetics Pharmaceuticals Inc., with 19 participants enrolled, started 2023-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: atumelnant.
Shares Crinetics Pharmaceuticals and the tag pipeline.
Shares Crinetics Pharmaceuticals and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.